Vokes Natalie I, Zhang Jianjun
Department of Thoracic and Head and Neck Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lung Cancer (Auckl). 2021 Dec 2;12:139-149. doi: 10.2147/LCTT.S272518. eCollection 2021.
Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require adjuvant chemotherapy or may in fact be incurable stage IV lesions. Conversely, MLTs that represent distinct primaries have a better prognosis and may be overtreated if inappropriately classified as related secondaries. Historically, pathologic and radiographic criteria were used to distinguish between primary and secondary MLTs; however, the advent of genomic profiling has demonstrated limitations to these historic classification systems. In this review, we discuss the use of molecular profiling to distinguish between primary and secondary lung cancers, with a focus on the insights gleaned from whole exome sequencing (WES) analyses. While WES is not yet feasible in routine clinical practice, WES studies have helped elucidate the clonal relationship between primary and secondary lung cancers and provide important context for the application of targeted sequencing panel-based analyses.
出现多发性肺肿瘤(MLTs)的非小细胞肺癌(NSCLC)对准确分期和预后提出了挑战。作为来自共同原发灶的克隆相关继发性转移灶出现的MLTs分期较高,通常需要辅助化疗,或者实际上可能是无法治愈的IV期病变。相反,代表不同原发灶的MLTs预后较好,如果被不恰当地归类为相关继发性肿瘤,可能会受到过度治疗。从历史上看,病理和影像学标准被用于区分原发性和继发性MLTs;然而,基因组分析的出现已证明这些历史分类系统存在局限性。在本综述中,我们讨论了使用分子分析来区分原发性和继发性肺癌,重点是从全外显子测序(WES)分析中获得的见解。虽然WES在常规临床实践中尚不可行,但WES研究有助于阐明原发性和继发性肺癌之间的克隆关系,并为基于靶向测序panel的分析应用提供重要背景。